FACT Complex-targeting Curaxin CBL0137

DRUG2 trials

Sponsors

Roswell Park Cancer Institute, Children's Oncology Group

Conditions

Advanced Cutaneous Melanoma of the ExtremityAdvanced Sarcoma of the ExtremityClinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Diffuse Midline Glioma, H3 K27-AlteredMetastatic Malignant Neoplasm in the Central Nervous SystemPathologic Stage IIIB Cutaneous Melanoma AJCC v8Pathologic Stage IIIC Cutaneous Melanoma AJCC v8

Phase 1

CBL0137 in Treating Patients With Advanced Extremity Melanoma or Sarcoma

TerminatedNCT03727789

Roswell Park Cancer InstituteAdvanced Cutaneous Melanoma of the Extremity, Advanced Sarcoma of the Extremity, Clinical Stage III Cutaneous Melanoma AJCC v8 +10

Start: 2019-07-01End: 2024-01-16Updated: 2024-03-27

CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

RecruitingNCT04870944

Children's Oncology GroupDiffuse Midline Glioma, H3 K27-Altered, Metastatic Malignant Neoplasm in the Central Nervous System, Recurrent Diffuse Intrinsic Pontine Glioma +7

Start: 2022-01-28End: 2026-12-31Target: 63Updated: 2026-09-11

Related Papers

A phase 1 trial of the FACT inhibitor CBL0137 in pediatric patients with relapsed or refractory solid and CNS tumors: A report from the Children’s Oncology Group study PEPN2111.

Journal of Clinical Oncology2025-05-28

DIPG-24. COMBINED EPIGENETIC THERAPY WITH FACT AND BET INHIBITORS REMODELS CHROMATIN AND DISRUPTS ONCOGENIC TRANSCRIPTION IN DIFFUSE MIDLINE GLIOMA

Neuro-Oncology2024-06-18

Abstract B016: Targeting the epigenome through combined Facilitates Chromatin Transcription (FACT) and Bromodomain and Extra-Terminal Domain (BET) inhibition in Diffuse Midline Glioma (DMG)

Cancer Research2024-03-04

DIPG-06. Uncovering the FACTs in Diffuse Midline Glioma (DMG)

Neuro-Oncology2022-06-01